Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Supratek Pharma

Next Previous
Drug Profile

Research programme: cancer therapeutics - Supratek Pharma

Alternative Names: SP-1014C; SP-1030C; SP-1031C; SP-1063C

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Supratek Pharma
  • Class
  • Mechanism of Action Alkylating agents; DNA topoisomerase I inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Prostate cancer

Most Recent Events

  • 23 Feb 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Canada (Parenteral) (Supratek Pharma website, February 2023)
  • 23 Feb 2023 Discontinued - Preclinical for Colorectal cancer in Canada (Parenteral) (Supratek Pharma website, February 2023)
  • 23 Feb 2023 Discontinued - Preclinical for Haematological malignancies in Canada (Parenteral) (Supratek Pharma website, February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top